Navigation Links
GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2007 Financial Results
Date:3/14/2008

DS vaccine technology and

composition are significantly different than the Merck & Co. Inc. AIDS

vaccines that recently had their human trials halted due to safety and

effectiveness concerns.

About GeoVax Labs, Inc.

GeoVax Inc. is an Atlanta, Georgia USA biotechnology company, established to develop, manufacture, license and commercialize human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents. GeoVax's vaccine technology is protected by 20 issued and filed patent applications.

For more information, contact the Company at (404) 727-0971 or visit http://www.geovax.com.

Safe Harbor Statement: All statements in this news release, not statements of historical fact, are forward-looking statements. These statements are based on expectations and assumptions as of the date of this press release and are subject to numerous risks and uncertainties which could cause actual results to differ materially from those described in the forward-looking statements. Risks and uncertainties include, but are not limited to, whether; GeoVax can develop and manufacture these vaccines with the desired characteristics in a timely manner, GeoVax's vaccines will be determined to be safe for use in humans, GeoVax's vaccines will be effective in preventing AIDS in humans, the vaccines will receive the regulatory approvals necessary to be licensed and marketed, GeoVax can raise the required capital to complete development of its vaccines, there is development of competitive products that may be more effective or easier to use than GeoVax's products, and other factors over which GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements, and does not intend to do so. Certain matters discussed in this news release are forward looking statements involving certain risks and uncertainties including, without limitation
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. GeoVax Vaccine Only 5th AIDS Vaccine Moving to Phase 2 Human Trials
2. Dr. Harriet Robinson Joins GeoVax Team as V.P. of R & D to Accelerate AIDS Vaccine Trials Program
3. GeoVax Labs, Inc. Selected by Georgia Bio as 2008 Deal of the Year Award Winner in Life Sciences Industry
4. GeoVax Labs, Inc. Selects Financial Relations Board as Investor Relations Counsel
5. GeoVax Labs, Inc. Third Quarter Financial Results and Operational Update
6. Excellent Results Received from GeoVaxs Full-Dose HIV/AIDS Vaccine Trial
7. GeoVax Labs, Inc. Comments on Discontinuance of Mercks HIV Vaccine Trial
8. GeoVax Successful HIV/AIDS Vaccine Trial Data Presented at AIDS Vaccine 2007 Conference
9. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
10. Memory Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results
11. PLC Systems Reports Fourth Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... Alemania, December 17, 2014 Los ... con un alto nivel de gasto en investigación y ... 2013/14 (finalizado el 30 de septiembre de 2014) ZEISS ... 4.287 millones de euros (año anterior: 4.190 millones de ... desfavorables. Las ganancias (EBIT) crecieron un 14 por ciento, ...
(Date:12/17/2014)... NEW YORK , Dec. 17, 2014 /PRNewswire-USNewswire/ ... resonance imaging (MRI), the MRI market is seeing ... cardiovascular and breast MRI scans account for the ... providing a higher resolution of images, which are creating ... resonance imaging (MRI) market is growing at a ...
(Date:12/17/2014)... N.J. , Dec. 17, 2014  IGI Laboratories, ... today the closing of its offering of $125 million ... 2019 (the "Notes").  The Notes were offered and sold ... under the Securities Act of 1933, as amended (the ... a fixed rate of 3.75% per year, payable semiannually ...
Breaking Medicine Technology:ZEISS confirma su posición en un entorno difícil 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 2IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 4
... PSTX) today announced that The Mount Sinai Hospital in New York City has implemented its Safety-Sponge System. , ... , , ... ... ...
... N.J. , March 15 Regado Biosciences, Inc., ... with active control agents, announced that Chris Rusconi , ... Zelenkofske , DO, FACC, Senior Vice President , Chief Medical ... on Monday, March 15, 2010 in Atlanta, ...
Cached Medicine Technology:Patient Safety Technologies, Inc., Contracts to Implement the Safety-Sponge(TM) System at The Mount Sinai Hospital in New York 2Patient Safety Technologies, Inc., Contracts to Implement the Safety-Sponge(TM) System at The Mount Sinai Hospital in New York 3Regado Biosciences, Inc. Introduces REG2, Its Second Product Candidate, at the American College of Cardiology Conference, 59th Annual Scientific Session, in Atlanta, Georgia on March 15, 2010 2Regado Biosciences, Inc. Introduces REG2, Its Second Product Candidate, at the American College of Cardiology Conference, 59th Annual Scientific Session, in Atlanta, Georgia on March 15, 2010 3Regado Biosciences, Inc. Introduces REG2, Its Second Product Candidate, at the American College of Cardiology Conference, 59th Annual Scientific Session, in Atlanta, Georgia on March 15, 2010 4
(Date:12/19/2014)... Wisconsin (PRWEB) December 19, 2014 After ... music performer is again returning to the stage to ... her husband for concert performances, and the successful tour ... was originally announced. , Visit Ticketability.com ... the newly-announced Detroit shows at fair prices. , Music ...
(Date:12/19/2014)... good shape seems to reduce your risk of high blood ... than 57,000 Americans, including more than 35,000 with high blood ... Those in the poorest shape had a more than 70 ... of the study, compared to a 50 percent chance for ... than 8,000 people diagnosed with high blood pressure during the ...
(Date:12/19/2014)... Dotinga HealthDay Reporter ... including ibuprofen, might slightly reduce your risk of developing ... of ibuprofen (Advil, Motrin) and naproxen (Aleve) appear to ... 15 percent, the researchers concluded after reviewing nine prior ... sun exposure. These painkillers "have potential ...
(Date:12/17/2014)... FL (PRWEB) December 17, 2014 While countless ... people do not realize the potential dangers of their purchase. ... valid prescription from a qualified doctor, but patients who buy ... the point that there is actually no real hCG present. ... States, where there are no safety standards and may contain ...
(Date:12/17/2014)... 17, 2014 HeartMath® Inc., recognized ... stress, heart rate variability (HRV), heart coherence and ... extensive HRV databases and algorithms to chipset manufacturers ... enable HeartMath’s partners to offer its HRV solutions, ... as well as its normative HRV databases and ...
Breaking Medicine News(10 mins):Health News:Garth Brooks Tickets for Joe Louis Arena: Ticketability.com Becomes a Popular Destination for Discount Tickets for Garth Brooks’ Detroit Concerts Set for February 27-28 2Health News:Being Fit Keeps Blood Pressure in Check 2Health News:Common Painkillers May Help Prevent Certain Skin Cancers, Study Finds 2Health News:Common Painkillers May Help Prevent Certain Skin Cancers, Study Finds 3Health News:Diet Doc Reveals the Real Dangers for Those who Buy hCG Online 2Health News:Diet Doc Reveals the Real Dangers for Those who Buy hCG Online 3Health News:HeartMath® Inc.’s HRV Platform Solutions Available for Licensing 2Health News:HeartMath® Inc.’s HRV Platform Solutions Available for Licensing 3
... June 24 Lightspeed Design, Inc. announces the release ... state-of-the-art capture and playback of HD 3D media. DepthQ(R) ... professional clients in corporate, entertainment, medical and industrial applications ... new DepthQ(R) family of stereoscopic software -- DepthQ(R)Capture(TM) and ...
... Dr. Marc Sarti from the University of Virginia ... to target small cancerous lung lesions that were located in extremely ... for the diagnosis and treatment for these patients was the first ... the lungs, small potential cancers are extremely difficult to access for ...
... every online purchase of new Maui Jim sunglasses results in a ... , LAHAINA, Hawaii, June 24 Effective today and extending ... Jim sunglasses from http://www.mauijim.com will ... to Unite for Sight, the preeminent non-profit group dedicated to improvement ...
... to participate in the Foundation,s Orange ... , NEW YORK, June 24 The Crohn,s & Colitis Foundation, ... from the second annual Celebrating UC Success essay contest. ... program that honors people who have found personal ways to manage ...
... Surveyed Physicians Will Increase Their Use of Carbapenems In ... from AMR and Decision Resources , , MALVERN, ... Arlington Medical Resources (AMR) and Decision Resources find ... a leading drug attribute that surveyed physicians prefer for ...
... Hard to Treat Diseases (HTDS.PK) www.htdsmedical.com - ... of recovering intellectual property (IP) rights that could provide ... Company retained a USA based IP consultant to attempt ... preferred shareholder and its corporate advisors, verily believe was ...
Cached Medicine News:Health News:Lightspeed Releases the New DepthQ(R) Family of Stereoscopic HD Video Software 2Health News:Lightspeed Releases the New DepthQ(R) Family of Stereoscopic HD Video Software 3Health News:Veran Medical Enables Breakthrough 4D Navigation to Cancer Lesions at University of Virginia Hospital 2Health News:Maui Jim Teams With Unite for Sight in New 'Buy One, Give One' Program to Improve Eye Health Amongst the World's Most Needy 2Health News:Maui Jim Teams With Unite for Sight in New 'Buy One, Give One' Program to Improve Eye Health Amongst the World's Most Needy 3Health News:The Crohn's & Colitis Foundation and Procter & Gamble Pharmaceuticals Announce 2009 Celebrating UC Success Contest Winners 2Health News:The Crohn's & Colitis Foundation and Procter & Gamble Pharmaceuticals Announce 2009 Celebrating UC Success Contest Winners 3Health News:The Crohn's & Colitis Foundation and Procter & Gamble Pharmaceuticals Announce 2009 Celebrating UC Success Contest Winners 4Health News:The Crohn's & Colitis Foundation and Procter & Gamble Pharmaceuticals Announce 2009 Celebrating UC Success Contest Winners 5Health News:Availability in Both Intravenous and Oral Formulation is a Leading Drug Attribute Surveyed Physicians Prefer for the Treatment of Urinary Tract Infections in the Hospital Setting 2Health News:Availability in Both Intravenous and Oral Formulation is a Leading Drug Attribute Surveyed Physicians Prefer for the Treatment of Urinary Tract Infections in the Hospital Setting 3Health News:Hard To Treat Diseases (HTDS.PK) To Regain Intellectual Property (IP) Ownership 2Health News:Hard To Treat Diseases (HTDS.PK) To Regain Intellectual Property (IP) Ownership 3
... design facilitates negotiation of the prostatic ... medium length olive Coude tip with ... latex construction provides added stiffness and ... in a variety of materials, eye ...
Used to provide bladder drainage by percutaneous placement of a balloon catheter. Supplied sterile in peel-open packages. Intended for one-time use....
Used to provide bladder drainage by percutaneous placement of a Malecot catheter. Supplied sterile in peel-open packages. Intended for one-time use....
Used for pulling sutures from a vaginal incision into the suprapubic area during bladder suspension surgery. Supplied sterile in peel-open packages....
Medicine Products: